Prothena/$PRTA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Prothena
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Ticker
$PRTA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Dublin, Ireland
Employees
163
Website
Prothena Metrics
BasicAdvanced
$360M
-
-$2.05
-0.08
-
Price and volume
Market cap
$360M
Beta
-0.08
52-week high
$25.41
52-week low
$4.32
Average daily volume
1.4M
Financial strength
Current ratio
9.001
Quick ratio
8.625
Long term debt to equity
1.731
Total debt to equity
2.331
Profitability
EBITDA (TTM)
-137.713
Gross margin (TTM)
-51.68%
Net profit margin (TTM)
-79.94%
Operating margin (TTM)
-100.49%
Effective tax rate (TTM)
4.83%
Revenue per employee (TTM)
$850,000
Management effectiveness
Return on assets (TTM)
-15.49%
Return on equity (TTM)
-23.46%
Valuation
Price to revenue (TTM)
2.605
Price to book
0.82
Price to tangible book (TTM)
0.82
Price to free cash flow (TTM)
-2.752
Free cash flow yield (TTM)
-36.34%
Free cash flow per share (TTM)
-242.75%
Growth
Revenue change (TTM)
54.55%
Earnings per share change (TTM)
-36.43%
3-year revenue growth (CAGR)
-11.88%
10-year revenue growth (CAGR)
21.79%
3-year earnings per share growth (CAGR)
15.17%
10-year earnings per share growth (CAGR)
2.87%
What the Analysts think about Prothena
Analyst ratings (Buy, Hold, Sell) for Prothena stock.
Bulls say / Bears say
Prothena expects initial Phase 1 ASCENT data for its wholly-owned PRX012 Alzheimer’s program in August 2025, which if positive could materially de-risk one of its leading pipeline assets and drive significant valuation upside.
Partner Roche has advanced prasinezumab into Phase 3 development for early-stage Parkinson’s disease, positioning Prothena to benefit from potential milestone payments and royalties pending successful trial outcomes.
Prothena’s partnerships carry up to $105 million in contingent milestone payments expected by 2026, providing non-dilutive financing catalysts as clinical programs progress and supporting the company’s cash runway.
The Phase 3 AFFIRM-AL trial for birtamimab failed to meet both its primary endpoint of time to all-cause mortality and its secondary endpoints, leading Prothena to discontinue its development and creating a significant void in its rare amyloid franchise.
The announcement of an approximate 63% workforce reduction as part of a corporate restructuring may delay development timelines across Prothena’s wholly-owned and partnered programs, potentially undermining program execution and increasing execution risk.
PRTA shares have declined over 53% year-to-date, reflecting waning investor confidence and heightening the risk of further downside absent compelling positive clinical or financial catalysts.
Data summarised monthly by Lightyear AI. Last updated on 20 Jul 2025.
Prothena Financial Performance
Revenues and expenses
Prothena Earnings Performance
Company profitability
Prothena News
AllArticlesVideos
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
Business Wire·1 month ago
Why Is Prothena Stock Trading Lower On Tuesday?
Benzinga·2 months ago
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Prothena stock?
Prothena (PRTA) has a market cap of $360M as of July 28, 2025.
What is the P/E ratio for Prothena stock?
The price to earnings (P/E) ratio for Prothena (PRTA) stock is 0 as of July 28, 2025.
Does Prothena stock pay dividends?
No, Prothena (PRTA) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Prothena dividend payment date?
Prothena (PRTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Prothena?
Prothena (PRTA) has a beta rating of -0.08. This means that it has an inverse relation to market volatility.